

**DEPARTMENT OF SOCIAL AND HEALTH SERVICES  
HEALTH AND RECOVERY SERVICES ADMINISTRATION  
Olympia, Washington**

**To:** Pharmacists  
All Prescribers  
Nursing Home Administrators  
Managed Care Organizations

**Memorandum No: 06-25**  
**Issued: April 27, 2006**

**From:** Douglas Porter, Assistant Secretary  
Health and Recovery Services  
Administration (HRSA)

**For information, contact Provider  
Relations at:** 800.562.3022 or  
<http://maa.dshs.wa.gov/contact/prucontact.asp>  
or visit the pharmacy web site at:  
<http://maa.dshs.wa.gov/pharmacy>

**Subject: Prescription Drug Program: Therapeutic Duplication of ADHD Therapy and Additions to the list of Limitations on Certain Drugs**

**Effective for claims with dates of service on and after June 1, 2006**, unless otherwise noted, HRSA will implement the following changes to the Prescription Drug Program:

- Prior authorization for therapeutic duplication of Attention Deficit Hyperactivity Disorder (ADHD) therapy; and
- Additions to the list of Limitations on Certain Drugs (age limits).

### **Therapeutic Duplication of ADHD Therapy**

**Beginning June 1, 2006**, the State will require Prior Authorization (PA) on combinations of 2 or more drugs used to treat ADHD\*. See the matrix below for those drug combinations that will require PA after 34 days of concurrent therapy. Pharmacies may request PA by contacting HRSA by fax at 360.725.2141 or by calling 800.848.2842 (option 1). HRSA may require additional clinical information to substantiate the PA request and will contact the prescribing provider to obtain that information, as necessary.

**Note:** Combinations of select ADHD drugs for children 17 years of age and younger will require a second opinion by an HRSA-designated mental health expert and the approval of the HRSA Medical Director.

### **Combinations of Medications in two or more ADHD Categories**

	<b>Methylphenidate</b>	<b>Dexmethylphenidate</b>	<b>Amphetamines</b>	<b>Strattera®</b>
<b>Methylphenidate</b>		PA	PA	PA
<b>Dexmethylphenidate</b>	PA		PA	PA
<b>Amphetamines</b>	PA	PA		PA
<b>Strattera®</b>	PA	PA	PA	

\* The decisions regarding therapeutic duplication of ADHD drugs were made by HRSA in consultation with experts in the Mental Health Drug Initiative workgroup.

## Additions to the List of Limitations on Certain Drugs

For claims submitted on or after June 1, 2006:

Drug	Limitations
Ambien <sup>®</sup> / CR ( <i>zolpidem tartrate</i> )	18 years of age or older
Estazolam	18 years of age or older
Flurazepam	18 years of age or older
Lunesta <sup>®</sup> ( <i>eszopiclone</i> )	18 years of age or older
Rozerem <sup>®</sup> ( <i>ramelteon</i> )	18 years of age or older
Doral <sup>®</sup> ( <i>quazepam</i> )	18 years of age or older
Sonata <sup>®</sup> ( <i>zaleplon</i> )	18 years of age or older
Temazepam	18 years of age or older
Triazolam	18 years of age or older

To view MAA's current list of Limitations on Certain Drugs,  
go to:

<http://maa.dshs.wa.gov/pharmacy/DrugAuth.htm>

## How do I conduct business electronically with HRSA?

You may conduct business electronically with HRSA by accessing WaMedWeb at  
<https://wamedweb.acs-inc.com>.

## How can I get HRSA's provider issuances?

To obtain DSHS/HRSA provider numbered memoranda and billing instruction, go to the DSHS/HRSA website at <http://hrsa.dshs.wa.gov> (click *the Billing Instructions and Numbered Memorandum* link). These may be downloaded and printed.